住院患者药物基因组学项目的实施模式
本文综述了建立住院药物基因组学服务的关键操作要素,并重点介绍药师在三家机构中提供基因导向药物治疗的角色。三家项目均采用反应性而非先发性基因检测,并遵循CPIC指南进行用药推荐。药师在推动实施、建立临床流程、解读检测结果及教育培训等方面发挥重要作用。
要点
- 药师在住院药物基因组学项目中承担推动实施、流程建立、结果解读与教育培训等关键角色。
- 三家项目均采用反应性基因检测,因当前第三方支付结构下该方式最可行。
- 所有项目均遵循CPIC指南,根据基因检测结果给出药物治疗推荐。
核心结论
- 药师应准备好作为解读和应用基因检测结果指导用药决策的专家。
- 门诊药师也应准备在照护过渡中协助基因导向药物治疗,因检测结果可能在患者出院后才可用。
研究设计与样本
- 本文为综述,回顾建立住院药物基因组学服务的关键操作要素,并介绍三家机构的药师角色。
主要发现
- 药师参与多层面工作,包括推动和领导实施、建立临床流程、协助解读基因检测结果并应用于处方决策、教育其他医护人员和患者。
- 项目包括将基因检测结果用于经皮冠状动脉介入治疗后优化抗血小板药物选择以及个体化华法林剂量。
- 三家住院药物基因组学项目均采用反应性而非先发性基因检测。
- 所有三家机构均遵循CPIC指南进行基于基因检测结果的药物治疗推荐。
关键数值与推荐
- 基于基因检测结果的药物治疗推荐遵循CPIC指南。
- 采用反应性而非先发性基因检测,因当前第三方支付结构下该方式最可行。
临床怎么用
- 药师应参与住院药物基因组学项目的实施,建立支持基因导向治疗的临床流程。
- 药师应协助临床人员解读基因检测结果并将其应用于处方决策。
- 药师应对其他医护人员和患者进行基因组医学教育。
- 门诊药师应在照护过渡中协助基因导向药物治疗,因检测结果可能在出院后才可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The operational elements essential for establishing an inpatient pharmacogenetic service are reviewed, and the role of the pharmacist in the provision of genotype-guided drug therapy in pharmacogenetics programs at three institutions is highlighted. SUMMARY: Pharmacists are well positioned to assume important roles in facilitating the clinical use of genetic information to optimize drug therapy given their expertise in clinical pharmacology and therapeutics. Pharmacists have assumed important roles in implementing inpatient pharmacogenetics programs. This includes programs designed to incorporate genetic test results to optimize antiplatelet drug selection after percutaneous coronary intervention and personalize warfarin dosing. Pharmacist involvement occurs on many levels, including championing and leading pharmacogenetics implementation efforts, establishing clinical processes to support genotype-guided therapy, assisting the clinical staff with interpreting genetic test results and applying them to prescribing decisions, and educating other healthcare providers and patients on genomic medicine. The three inpatient pharmacogenetics programs described use reactive versus preemptive genotyping, the most feasible approach under the current third-party payment structure. All three sites also follow Clinical Pharmacogenetics Implementation Consortium guidelines for drug therapy recommendations based on genetic test results. CONCLUSION: With the clinical emergence of pharmacogenetics into the inpatient setting, it is important that pharmacists caring for hospitalized patients are well prepared to serve as experts in interpreting and applying genetic test results to guide drug therapy decisions. Since genetic test results may not be available until after patient discharge, pharmacists practicing in the ambulatory care setting should also be prepared to assist with genotype-guided drug therapy as part of transitions in care.
引用
- Cavallari LH, Lee CR, Duarte JD, et al. Implementation of inpatient models of pharmacogenetics programs. Am J Health Syst Pharm. 2016. PMID: 27864202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。